UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 9.054

Sortiert nach

Risk stratification of pT1-3N0 patients after radical cystectomy for adjuvant chemotherapy counselling

British journal of cancer, 2012-11, Vol.107 (11), p.1826-1832

2012

Volltextzugriff (PDF)

Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer

World journal of urology, 2017-03, Vol.35 (3), p.367-378

2017

Volltextzugriff (PDF)

Phase III double-blind study evaluating lens opacifications (LO) in patients with nonmetastatic prostate cancer (PCa) receiving denosumab (Dmab) for bone loss due to androgen deprivation therapy (ADT)

Annals of oncology, 2018-10, Vol.29, p.viii295-viii296

2018

Volltextzugriff (PDF)

Folate hydrolase‐1 (FOLH1) is a novel target for antibody‐based brachytherapy in Merkel cell carcinoma

Skin health and disease, 2021-03, Vol.1 (1), p.n/a

2021

Volltextzugriff (PDF)

TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes

Annals of oncology, 2024-04, Vol.35 (4), p.392-401

2024

Volltextzugriff (PDF)

Cytotoxic chemotherapy in the treatment of advanced renal cell carcinoma in the era of targeted therapy

Critical reviews in oncology/hematology, 2015-12, Vol.96 (3), p.518-526

2015

Volltextzugriff (PDF)

Clinico-genomic profiling and outcome prediction of neuroendocrine prostate cancer (NEPC)

Annals of oncology, 2018-10, Vol.29, p.viii293-viii294

2018

Volltextzugriff (PDF)

Boning up on prognostic factors in advanced renal cell carcinoma

Annals of oncology, 2011-04, Vol.22 (4), p.751-753

Tagawa, S.T.

2011

Volltextzugriff (PDF)

Phase I dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC)

Annals of oncology, 2018-10, Vol.29, p.viii274-viii274

2018

Volltextzugriff (PDF)

Synthetic DNA immunotherapy in biochemically relapsed prostate cancer

Annals of oncology, 2018-10, Vol.29, p.viii290-viii290

2018

Volltextzugriff (PDF)

Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma

The New England journal of medicine, 2019-07, Vol.381 (4), p.338-348

2019

Volltextzugriff (PDF)

Anti-prostate-specific membrane antigen (PSMA) monoclonal antibody (mAb) J591 immunotherapy for prostate cancer

Annals of oncology, 2016-10, Vol.27, p.vi265-vi265

2016

Volltextzugriff (PDF)

A phase 2 study of the aurora kinase A inhibitor alisertib for patients with neuroendocrine prostate cancer (NEPC)

Annals of oncology, 2016-10, Vol.27, p.vi565-vi565

2016

Volltextzugriff (PDF)

Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody

Lab on a chip, 2010-01, Vol.10 (1), p.27-29

2010

Volltextzugriff (PDF)

PO-43 - Differential coagulation factor expression in neuroendocrine prostate cancer (PC), metastatic castrate-resistant PC, and localized prostatic adenocarcinoma

Thrombosis research, 2016-04, Vol.140, p.S192-S192

2016

Volltextzugriff (PDF)

Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer

Neoplasia (New York, N.Y.), 2013-01, Vol.15 (1), p.1

2013

Volltextzugriff (PDF)

OC-14 - Baseline D-dimer levels are predictive of recurrent venous thromboembolism (VTE) at 6 months in cancer patients with VTE treated with tinzaparin

Thrombosis research, 2016-04, Vol.140, p.S174-S174

2016

Volltextzugriff (PDF)

Targeted Therapy for Locally Advanced or Metastatic Urothelial Cancer (mUC): Therapeutic Potential of Sacituzumab Govitecan

OncoTargets and therapy, 2022-01, Vol.15, p.1531-1542

2022

Volltextzugriff (PDF)

845PPhase III double-blind study evaluating lens opacifications (LO) in patients with nonmetastatic prostate cancer (PCa) receiving denosumab (Dmab) for bone loss due to androgen deprivation therapy (ADT)

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Microtubule inhibitor-based antibody-drug conjugates for cancer therapy

OncoTargets and therapy, 2014-01, Vol.7 (default), p.2227-2236

2014

Volltextzugriff (PDF)

Final phase II results of NCI 6981: A phase I/II study of sorafenib (S) plus gemcitabine (GEM) and capecitabine (CAP) for advanced renal cell carcinoma (RCC)

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.e15165-e15165

2011

Volltextzugriff (PDF)

Molecular characterization of neuroendocrine prostate cancer (NEPC) and identification of new drug targets

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.4536-4536

2011

Volltextzugriff (PDF)

Molecular characterization of neuroendocrine prostate cancer (NEPC) and identification of new drug targets

Journal of clinical oncology, 2011-03, Vol.29 (7_suppl), p.19-19

2011

Volltextzugriff (PDF)

Prognostic factors of cancer recurrence and progression in non-muscle-invasive urothelial carcinoma: A multicenter study of over 4,300 patients

Journal of clinical oncology, 2011-03, Vol.29 (7_suppl), p.249-249

2011

Volltextzugriff (PDF)

NCI 6896: A phase I trial of suberoylanilide hydroxamic acid (SAHA) and 13-cis retinoic acid in the treatment of patients with advanced renal cell carcinoma (RCC)

Journal of clinical oncology, 2011-03, Vol.29 (7_suppl), p.349-349

2011

Volltextzugriff (PDF)

1 – 25 von 9.054

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(6.254)
Mit Volltextzugriff
(8.083)

Publikationsform

6 weitere anzeigen...

Weniger anzeigen...

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Electronic Journals Library
(4.514)
Ingenta
(2.864)
MEDLINE
(2.823)
Journals@Ovid
(1.614)
NUS Single-Journal Subscriptions
(1.426)
Elsevier ScienceDirect Journals Complete
(1.425)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(1.048)
IngentaConnect Journals
(905)
Wiley Online Library All Journals
(811)
SpringerLink_现刊
(590)
IEEE Xplore
(511)
Wiley Online Library Full Collection 2018
(502)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(434)
Oxford Journals
(211)
Nature - Journals : Nature ; Nature Climate Change
(207)
Taylor & Francis Journals Auto-Holdings Collection
(153)
Taylor & Francis Journals Complete
(147)
Taylor & Francis
(139)
Nexis
(107)
American Institute of Physics (AIP) Journals
(99)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(48)
... seit 30 Tagen
(19)

Menü

Weitere Dienste

Einstellungen

Risk stratification of pT1-3N0 patients after radical cystectomy for adjuvant chemotherapy counselling

Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer

Phase III double-blind study evaluating lens opacifications (LO) in patients with nonmetastatic prostate cancer (PCa) receiving denosumab (Dmab) for bone loss due to androgen deprivation therapy (ADT)

Folate hydrolase‐1 (FOLH1) is a novel target for antibody‐based brachytherapy in Merkel cell carcinoma

TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes

Cytotoxic chemotherapy in the treatment of advanced renal cell carcinoma in the era of targeted therapy

Clinico-genomic profiling and outcome prediction of neuroendocrine prostate cancer (NEPC)

Boning up on prognostic factors in advanced renal cell carcinoma

Phase I dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC)

Synthetic DNA immunotherapy in biochemically relapsed prostate cancer

Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma

Anti-prostate-specific membrane antigen (PSMA) monoclonal antibody (mAb) J591 immunotherapy for prostate cancer

A phase 2 study of the aurora kinase A inhibitor alisertib for patients with neuroendocrine prostate cancer (NEPC)

Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody

PO-43 - Differential coagulation factor expression in neuroendocrine prostate cancer (PC), metastatic castrate-resistant PC, and localized prostatic adenocarcinoma

Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer

OC-14 - Baseline D-dimer levels are predictive of recurrent venous thromboembolism (VTE) at 6 months in cancer patients with VTE treated with tinzaparin

Targeted Therapy for Locally Advanced or Metastatic Urothelial Cancer (mUC): Therapeutic Potential of Sacituzumab Govitecan

845PPhase III double-blind study evaluating lens opacifications (LO) in patients with nonmetastatic prostate cancer (PCa) receiving denosumab (Dmab) for bone loss due to androgen deprivation therapy (ADT)

Microtubule inhibitor-based antibody-drug conjugates for cancer therapy

Final phase II results of NCI 6981: A phase I/II study of sorafenib (S) plus gemcitabine (GEM) and capecitabine (CAP) for advanced renal cell carcinoma (RCC)

Molecular characterization of neuroendocrine prostate cancer (NEPC) and identification of new drug targets

Molecular characterization of neuroendocrine prostate cancer (NEPC) and identification of new drug targets

Prognostic factors of cancer recurrence and progression in non-muscle-invasive urothelial carcinoma: A multicenter study of over 4,300 patients

NCI 6896: A phase I trial of suberoylanilide hydroxamic acid (SAHA) and 13-cis retinoic acid in the treatment of patients with advanced renal cell carcinoma (RCC)

Suchergebnisse filtern